Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search

Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Gut and liver Ročník 19; číslo 6; s. 783 - 794
Hlavní autori: Kim, Bokyung, Huh, Jung, Kim, Sang Gyun, Ahn, Ji Yong, Kim, Ji Won
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Korea (South) Gastroenterology Council for Gut and Liver 15.11.2025
거트앤리버 소화기연관학회협의회
Predmet:
Gastric Mucosa - drug effects
Gastritis - drug therapy
gastritis; pharmacologic treatment
Histamine H2 Antagonists - therapeutic use
Humans
Proton Pump Inhibitors - therapeutic use
내과학
Pharmacologic treatment
Gastritis
ISSN:1976-2283, 2005-1212, 2005-1212
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1976-2283
2005-1212
2005-1212
DOI:10.5009/gnl250267